Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 2
2015 1
2016 7
2017 10
2018 9
2019 4
2020 4
2021 10
2022 4
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Results by year

Filters applied: . Clear all
Page 1
Conversion Surgery in Gastric Cancer Carcinomatosis.
Morgagni P, Solaini L, Saragoni L, Monti M, Valgiusti M, Vittimberga G, Frassineti GL, Framarini M, Ercolani G. Morgagni P, et al. Among authors: valgiusti m. Front Oncol. 2022 Mar 8;12:852559. doi: 10.3389/fonc.2022.852559. eCollection 2022. Front Oncol. 2022. PMID: 35356199 Free PMC article.
Immune Checkpoints as a Target for Colorectal Cancer Treatment.
Passardi A, Canale M, Valgiusti M, Ulivi P. Passardi A, et al. Among authors: valgiusti m. Int J Mol Sci. 2017 Jun 21;18(6):1324. doi: 10.3390/ijms18061324. Int J Mol Sci. 2017. PMID: 28635639 Free PMC article. Review.
Analysis of EVs from patients with advanced pancreatic cancer identifies antigens and miRNAs with predictive value.
Vannini I, Rossi T, Melloni M, Valgiusti M, Urbini M, Passardi A, Bartolini G, Gallio C, Azzali I, Bandini S, Ancarani V, Montanaro L, Frassineti GL, Fabbri F, Rapposelli IG. Vannini I, et al. Among authors: valgiusti m. Mol Ther Methods Clin Dev. 2023 May 11;29:473-482. doi: 10.1016/j.omtm.2023.05.009. eCollection 2023 Jun 8. Mol Ther Methods Clin Dev. 2023. PMID: 37273899 Free PMC article.
Inflammatory indices as prognostic markers in metastatic colorectal cancer patients treated with chemotherapy plus Bevacizumab.
Passardi A, Azzali I, Bittoni A, Marisi G, Rebuzzi F, Molinari C, Bartolini G, Matteucci L, Sullo FG, Debonis SA, Gallio C, Monti M, Valgiusti M, Muratore M, Rapposelli IG, Ulivi P, Frassineti GL. Passardi A, et al. Among authors: valgiusti m. Ther Adv Med Oncol. 2023 Dec 11;15:17588359231212184. doi: 10.1177/17588359231212184. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 38107830 Free PMC article.
Antiangiogenic agents after first line and sorafenib plus chemoembolization: a systematic review.
Casadei Gardini A, Santini D, Aprile G, Silvestris N, Felli E, Foschi FG, Ercolani G, Marisi G, Valgiusti M, Passardi A, Puzzoni M, Silletta M, Brunetti O, Cardellino GG, Frassineti GL, Scartozzi M. Casadei Gardini A, et al. Among authors: valgiusti m. Oncotarget. 2017 Jul 22;8(39):66699-66708. doi: 10.18632/oncotarget.19449. eCollection 2017 Sep 12. Oncotarget. 2017. PMID: 29029548 Free PMC article. Review.
Interplay Between SIRT-3, Metabolism and Its Tumor Suppressor Role in Hepatocellular Carcinoma.
De Matteis S, Granato AM, Napolitano R, Molinari C, Valgiusti M, Santini D, Foschi FG, Ercolani G, Vespasiani Gentilucci U, Faloppi L, Scartozzi M, Frassineti GL, Casadei Gardini A. De Matteis S, et al. Among authors: valgiusti m. Dig Dis Sci. 2017 Aug;62(8):1872-1880. doi: 10.1007/s10620-017-4615-x. Epub 2017 May 19. Dig Dis Sci. 2017. PMID: 28527050 Free article. Review.
Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?
Marisi G, Cucchetti A, Ulivi P, Canale M, Cabibbo G, Solaini L, Foschi FG, De Matteis S, Ercolani G, Valgiusti M, Frassineti GL, Scartozzi M, Casadei Gardini A. Marisi G, et al. Among authors: valgiusti m. World J Gastroenterol. 2018 Sep 28;24(36):4152-4163. doi: 10.3748/wjg.v24.i36.4152. World J Gastroenterol. 2018. PMID: 30271080 Free PMC article. Review.
Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma.
Canale M, Ulivi P, Foschi FG, Scarpi E, De Matteis S, Donati G, Ercolani G, Scartozzi M, Faloppi L, Passardi A, Tamburini E, Valgiusti M, Marisi G, Frassineti GL, Casadei Gardini A. Canale M, et al. Among authors: valgiusti m. Crit Rev Oncol Hematol. 2018 Sep;129:44-53. doi: 10.1016/j.critrevonc.2018.06.017. Epub 2018 Jun 23. Crit Rev Oncol Hematol. 2018. PMID: 30097237 Free article. Review.
Sequential Treatment of Sorafenib-Regorafenib Versus Sorafenib-Physician's Choice: A Propensity Score-Matched Analysis.
Bang Y, Yoo C, Lonardi S, Kim HD, Vivaldi C, Rimini M, Frassineti GL, Park SR, Rizzato MD, Ryu MH, Salani F, Rapposelli IG, Ryoo BY, Zagonel V, Massa V, Valgiusti M, Burgio V, Scartozzi M, Cascinu S, Casadei-Gardini A. Bang Y, et al. Among authors: valgiusti m. Target Oncol. 2021 May;16(3):401-410. doi: 10.1007/s11523-021-00797-3. Epub 2021 Mar 1. Target Oncol. 2021. PMID: 33646487
52 results